Henrotin Yves, Hauzeur Jean-Philippe, Bruel Pierre, Appelboom Thierry
Physical Therapy and Rehabilitation Department, Princess Paola Hospital, Vivalia, Marche-en-Famenne, Bone and Cartilage Research Unit, University of Liège Institute of Pathology, level 5, CHU Sart-Tilman, 4000, Liège, Belgium.
BMC Res Notes. 2012 Aug 4;5:407. doi: 10.1186/1756-0500-5-407.
This pilot open noncontrolled study was designed to assess the efficacy of intra-articular injections of a solution combining hyaluronic acid (HA) and chondroitin sulphate (CS) in the treatment of outpatients affected by knee osteoarthrosis.
Thirty patients with knee OA have been included. The primary objective was to assess clinical efficacy as measured by pain and Lequesne's index. Secondary objectives were to assess potential effect of the treatment on ultrasound parameters, safety and biomarkers of cartilage metabolism and joint inflammation. After a selection visit (V1), the study treatment was administered 3 times on a weekly basis (V2, V3, V4). Follow-up was planned 6 (V5) and 12 weeks (V6) after the first intra-articular injection. Efficacy results showed a reduction in mean pain at V3 and V6 and in functional impairment, the most marked changes being measured at the two follow-up visits (V5 and V6). Although statistical significance was not achieved due to small sample size, a clear tendency towards improvement was detectable for ultrasound assessments as well as biomarkers. Except for a mild injection site hematoma for which the drug causal relationship could not be excluded, no adverse effect of clinical relevance was recorded during the study.
Although this pilot study was performed according to an open design only, the ultrasound as well as biomarkers changes strongly suggest a non-placebo effect. These preliminary results call now for a randomized controlled study to confirm the clinical relevance of the observed results.
#ISRCTN91883031.
本初步开放性非对照研究旨在评估关节腔内注射透明质酸(HA)和硫酸软骨素(CS)混合溶液治疗膝关节骨关节炎门诊患者的疗效。
纳入了30例膝关节骨关节炎患者。主要目标是评估以疼痛和勒奎恩指数衡量的临床疗效。次要目标是评估该治疗对超声参数、软骨代谢和关节炎症生物标志物的潜在影响、安全性。在筛选访视(V1)后,每周进行3次研究治疗(V2、V3、V4)。计划在首次关节腔内注射后6周(V5)和12周(V6)进行随访。疗效结果显示V3和V6时平均疼痛以及功能障碍有所减轻,在两次随访(V5和V6)时变化最为明显。尽管由于样本量小未达到统计学显著性,但超声评估以及生物标志物有明显的改善趋势。除了无法排除药物因果关系的轻度注射部位血肿外,研究期间未记录到具有临床相关性的不良反应。
尽管本初步研究仅采用开放性设计,但超声以及生物标志物的变化强烈提示存在非安慰剂效应。这些初步结果现在需要进行随机对照研究以证实所观察结果的临床相关性。
#ISRCTN91883031